Clinical Trial: Efficacy and Safety of the Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in the Treatment of Primary Erythromelalgia: A Clinical Study (China)

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy and Safety of the Calcitonin Gene-Related Peptide Receptor Antagonist Rimegepant in the Treatment of Primary Erythromelalgia: A Clinical Study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129784

Registration Time: 2026/08/10

Type: Interventional study

Primary Sponsor: Institute of Dermatology and Hospital for Skin Diseases,Chinese Academy of Medical Sciences & Peking Union Medical College

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337448

Published by HT Digital Content Services with permission from Health Daily Digest....